These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25918016)

  • 1. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.
    Cariani E; Roli L; Missale G; Villa E; Ferrari C; Trenti T
    Pharmacogenomics J; 2016 Feb; 16(1):18-29. PubMed ID: 25918016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
    Domagalski K; Pawłowska M; Tretyn A; Halota W; Pilarczyk M; Smukalska E; Linkowska K; Grzybowski T
    Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):745-54. PubMed ID: 23314745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
    Shi KQ; Liu WY; Lin XF; Fan YC; Chen YP; Zheng MH
    Gene; 2012 Oct; 507(1):27-35. PubMed ID: 22842190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
    Jung YK; Kim JH; Ahn SM; Yang JW; Park SJ; Kim JW; Yeon JE; Kwon OS; Kim YS; Choi DJ; Kim JH; Byun KS
    J Clin Gastroenterol; 2013 Aug; 47(7):644-50. PubMed ID: 23442843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?
    Garcia RF; Moreira S; de Araújo Ramos AL; Ferreira LE; de Mattos AA; Tovo CV; Nader LA; Ramos JA; Rondinelli E; de Jesus Dominici A; Garcia CE; de Souza Leite Pinho M; Brandão-Mello CE; Villela-Nogueira CA; de França PH
    World J Gastroenterol; 2013 Nov; 19(42):7399-404. PubMed ID: 24259970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.
    Ridruejo E; Solano A; Marciano S; Galdame O; Adrover R; Cocozzella D; Delettieres D; Martínez A; Gadano A; Mandó OG; Silva MO
    Ann Hepatol; 2011; 10(4):452-7. PubMed ID: 21911885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.
    Liu T; Sha K; Yang L; Wang Y; Zhang L; Liu X; Yang F
    PLoS One; 2014; 9(3):e91316. PubMed ID: 24642705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
    Huang CF; Yeh ML; Hsieh MH; Hsieh MY; Lin ZY; Chen SC; Wang LY; Huang JF; Juo SH; Lin YC; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2013 Sep; 28(9):1515-20. PubMed ID: 23560893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.
    Bota S; Sporea I; Şirli R; Neghină AM; Popescu A; Străin M
    Clin Drug Investig; 2013 May; 33(5):325-31. PubMed ID: 23532802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.
    Rangnekar AS; Fontana RJ
    J Viral Hepat; 2013 Jun; 20(6):377-84. PubMed ID: 23647954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.
    Cheng CH; Lin CC; Chen HL; Lin IT; Wu CH; Lee YK; Wong MW; Bair MJ
    Kaohsiung J Med Sci; 2017 Oct; 33(10):510-515. PubMed ID: 28962822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
    Lin CY; Chen JY; Lin TN; Jeng WJ; Huang CH; Huang CW; Chang SW; Sheen IS
    PLoS One; 2011 Mar; 6(3):e18322. PubMed ID: 21479134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.
    Ladero JM; Martin EG; Fernández C; Carballo M; Devesa MJ; Martínez C; Suárez A; Díaz-Rubio M; Agúndez JA
    J Gastroenterol Hepatol; 2012 Feb; 27(2):279-85. PubMed ID: 21722179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
    Yu ML; Huang CF; Huang JF; Chang NC; Yang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Li YN; Wu MS; Dai CY; Juo SH; Chuang WL
    Hepatology; 2011 Jan; 53(1):7-13. PubMed ID: 21254157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.